MYND Life Sciences Inc
CNSX:MYND
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
MYND Life Sciences Inc
Free Cash Flow
MYND Life Sciences Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MYND Life Sciences Inc
CNSX:MYND
|
Free Cash Flow
-CA$198.3k
|
CAGR 3-Years
-314%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oncolytics Biotech Inc
TSX:ONC
|
Free Cash Flow
-CA$24.7m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
R
|
Revive Therapeutics Ltd
CNSX:RVV
|
Free Cash Flow
-CA$230.5k
|
CAGR 3-Years
70%
|
CAGR 5-Years
44%
|
CAGR 10-Years
20%
|
|
|
Avicanna Inc
TSX:AVCN
|
Free Cash Flow
-CA$1.4m
|
CAGR 3-Years
42%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cannabix Technologies Inc
CNSX:BLO
|
Free Cash Flow
-CA$1.9m
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Microbix Biosystems Inc
TSX:MBX
|
Free Cash Flow
-CA$4.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-1%
|
|
MYND Life Sciences Inc
Glance View
MYND Life Sciences, Inc. is a neuro-pharmaceutical drug development company. The company is headquartered in Kelowna, British Columbia. The company went IPO on 2021-05-26. The firm is focused on conducting research linking depression and inflammation at the genetic and cellular level to develop a pharmaceutical treatment utilizing compounds found in psychedelics with the initial focus being on psilocybin and its various analogs. The company is working on advancing medicines based on neuro-anti-inflammatory substances through rigorous science and clinical trials with an initial focus on Major Depressive Disorder (MDD). The Company’s lead development program, referred to as the Human Mycogene Modulation program (HMM), is designed to treat neuropsychiatric disorders through the dosing of formulations of psilocybin. The company is evaluating additional indications for its HMM program, including autoimmune disorders (AD) and other MDD conditions.
See Also
What is MYND Life Sciences Inc's Free Cash Flow?
Free Cash Flow
-198.3k
CAD
Based on the financial report for Oct 31, 2023, MYND Life Sciences Inc's Free Cash Flow amounts to -198.3k CAD.
What is MYND Life Sciences Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
-314%
Over the last year, the Free Cash Flow growth was 89%. The average annual Free Cash Flow growth rates for MYND Life Sciences Inc have been -314% over the past three years .
